{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"77.2","value":"76.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Duration of objective response (OR) was measured from the time the criteria for CR or PR (whichever was documented first) were first met until the first date that progressive disease or death (or date of censoring for PFS) was objectively documented as per independent review.","dispersionType":"Standard Deviation","groups":[{"description":"Patients in the four initial cohorts are combined in the efficacy presentations. Patients start once daily oral treatment of BIBW 2992 (Afatinib) at 50 mg before protocol amendment 2 (17 Dec 2008), until progression or undue adverse events (AEs) development. Patients can be dose-reduced up to two times if needed after temporary interruption of treatment due to drug- related AEs. After protocol amendment 2, the starting dose of BIBW 2992 was reduced to 40 mg, with 2 possible dose reductions if needed after temporary dose interruption due to drug-related AEs.","id":"OG000","title":"Afatinib"}],"paramType":"MEAN","populationDescription":"Treated set including only patients with objective response.","reportingStatus":"POSTED","timeFrame":"Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.","title":"Duration of Objective Response","type":"SECONDARY","unitOfMeasure":"Weeks"}